187 related articles for article (PubMed ID: 24300078)
21. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
Dai YC; Wang SC; Haque MM; Lin WH; Lin LC; Chen CH; Liu YW
PLoS One; 2017; 12(10):e0186214. PubMed ID: 29016672
[TBL] [Abstract][Full Text] [Related]
22. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele.
Ozaki K; Sukata T; Yamamoto S; Uwagawa S; Seki T; Kawasaki H; Yoshitake A; Wanibuchi H; Koide A; Mori Y; Fukushima S
Cancer Res; 1998 Sep; 58(17):3806-11. PubMed ID: 9731488
[TBL] [Abstract][Full Text] [Related]
23. DNA methylation adduct formation and H-ras gene mutations in progression of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder tumors caused by a single exposure to N-methyl-N-nitrosourea.
Shibata MA; Shirai T; Ogawa K; Takahashi S; Wild CP; Montesano R; Tsuda H; Ito N
Carcinogenesis; 1994 Dec; 15(12):2965-8. PubMed ID: 8001265
[TBL] [Abstract][Full Text] [Related]
24. Influence of total dose and dose schedule on induction of urinary bladder cancer in the mouse by N-butyl-N-(4-hydroxybutyl)nitrosamine.
McCormick DL; Ronan SS; Becci PJ; Moon RC
Carcinogenesis; 1981; 2(3):251-4. PubMed ID: 7273310
[TBL] [Abstract][Full Text] [Related]
25. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model.
McConnell EJ; Pathangey LB; Madsen CS; Gendler SJ; Mukherjee P
J Surg Res; 2002 Oct; 107(2):196-202. PubMed ID: 12429175
[TBL] [Abstract][Full Text] [Related]
26. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases.
Shi FF; Gunn GR; Snyder LA; Goletz TJ
Vaccine; 2007 Apr; 25(17):3338-46. PubMed ID: 17292519
[TBL] [Abstract][Full Text] [Related]
27. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice.
Tempero RM; VanLith ML; Morikane K; Rowse GJ; Gendler SJ; Hollingsworth MA
J Immunol; 1998 Nov; 161(10):5500-6. PubMed ID: 9820526
[TBL] [Abstract][Full Text] [Related]
28. Possible rare involvement of O6-methylguanine formation as a significant mutational factor in mouse urinary bladder carcinogenesis models.
Chen T; Yamamoto S; Kitano M; Murai T; Wanibuchi H; Matsukuma S; Nakatsuru Y; Ishikawa T; Fukushima S
Teratog Carcinog Mutagen; 1998; 18(3):101-10. PubMed ID: 9728794
[TBL] [Abstract][Full Text] [Related]
29. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
30. Treatment with mANT2 shRNA enhances antitumor therapeutic effects induced by MUC1 DNA vaccination.
Choi Y; Jeon YH; Jang JY; Chung JK; Kim CW
Mol Ther; 2011 May; 19(5):979-89. PubMed ID: 21063392
[TBL] [Abstract][Full Text] [Related]
31. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
32. Metallothionein modulates the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine in mice.
Kondo Y; Himeno S; Endo W; Mita M; Suzuki Y; Nemoto K; Akimoto M; Lazo JS; Imura N
Carcinogenesis; 1999 Aug; 20(8):1625-7. PubMed ID: 10426817
[TBL] [Abstract][Full Text] [Related]
33. Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.
Saito S; Tazaki H; Heston WD; Fair WR
Int J Urol; 1996 Jan; 3(1 Suppl):S35-9. PubMed ID: 24304018
[TBL] [Abstract][Full Text] [Related]
34. Low susceptibility of nude mice to induction of invasive urinary bladder cancers by N-ethyl-N-(4-hydroxybutyl)nitrosamine.
Tamano S; Shirai T; Kawabe M; Ni-I H; Mori Y; Okada M; Fukushima S
Toxicol Pathol; 1992; 20(2):205-11. PubMed ID: 1475581
[TBL] [Abstract][Full Text] [Related]
35. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
[TBL] [Abstract][Full Text] [Related]
36. N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder cancer in C57BL/6 X DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoids.
Becci PJ; Thompson HJ; Strum JM; Brown CC; Sporn MB; Moon RC
Cancer Res; 1981 Mar; 41(3):927-32. PubMed ID: 7459879
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
38. Conditional Expression of the Androgen Receptor Increases Susceptibility of Bladder Cancer in Mice.
Johnson DT; Hooker E; Luong R; Yu EJ; He Y; Gonzalgo ML; Sun Z
PLoS One; 2016; 11(2):e0148851. PubMed ID: 26862755
[TBL] [Abstract][Full Text] [Related]
39. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.
Lakshminarayanan V; Thompson P; Wolfert MA; Buskas T; Bradley JM; Pathangey LB; Madsen CS; Cohen PA; Gendler SJ; Boons GJ
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):261-6. PubMed ID: 22171012
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
